Table 3 Summary of published C. haemolyticum infections
Year of report | Country | Age | Comorbidity | Diagnosis | Therapy | Outcome | Reference number | |
|---|---|---|---|---|---|---|---|---|
1 | 2008 | USA | Unknown | Unknown | Unknown | Unknown | Unknown | 2 |
2 | 2013 | Japan | 26 | None | Necrotizing fasciitis | (1) Ampicillin/sulbactam + minocycline (2) Ceftazidime (3) Ciprofloxacin + gentamicin (4) Ciprofloxacin | Survived | 1 |
3 | 2014 | Thailand | 4 | None | Proctocolitis | (1) Ceftriaxone (2) Ceftriaxone + ciprofloxacin + metronidazole | Survived | 6 |
4 | 2015 | Japan | 69 | Cerebral infarction, hypertension | Pneumonia | (1) Ampicillin/sulbactam (2) Meropenem (3) Piperacillin/tazobactam | Survived | 5 |
5 | 2016 | USA | 11 | Congenital heart disease, endocarditis | Bacteremia | (1) Ceftriaxone (2) Meropenem + gentamicin + sulfamethoxazole/trimethoprim (3) Ceftriaxone + levofloxacin | Survived | 4 |
6 | 2020 | Japan | 70s | Hypertension, diabetes, benign prostatic hyperplasia | Pneumonia | (1) Meropenem + levofloxacin (2) Ceftazidime + levofloxacin (3) Levofloxacin | Survived | 3 |
7 | This study | Japan | 73 | Alcoholic hepatitis, hyperglycemia, hypertension | Meningitis | Meropenem + vancomycin | Died | – |